ACXP Stock — Acurx Pharmaceuticals Inc.: Cash, EV, Pipeline

Share price

$1.39

Market cap

$7.7M

Cash

$10.7M

Enterprise value

-$3.0M

Balance sheet

Cash	$10.7M
Debt	$0.0M
Net cash	$10.7M
Enterprise value	-$3.0M
Basic shares	4.7M shares
Fully diluted shares	8.3M shares
Fully diluted market cap	$11.5M
Cash per share	$2.27

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading ACXP daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Nov 10 - Dec 22	Ibezapolstat	Phase 2	Clostridium Difficile Infection Recurrence	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

Ibezapolstat

Phase 2 · Active Modality: small molecule (antibiotic)

Aliases ACX-362E, GLS362E

Target DNA polymerase IIIC (pol IIIC)

Indications

C. difficile infection (CDI) (Phase 2)
Recurrent C. difficile infection (rCDI) (Phase 2)

Catalysts

— Q4 2026

Status note Phase 2 CDI trial completed. Company plans a pivotal Phase 3 in rCDI under FDA's LPAD pathway following the rCDI pilot; open-label pilot trial startup began Q2 2026 with first patient expected Q4 2026. Originated via Feb 2018 asset purchase from GLSynthesis.

ACX-375C

Preclinical · Active Modality: small molecule (antibiotic)

Target DNA polymerase IIIC (pol IIIC)

Indications

Gram-positive bacterial infections (MRSA, VRE, PRSP, anthrax) (Preclinical)

Status note Early-stage candidate for oral and/or parenteral treatment of Gram-positive infections including MRSA, VRE, penicillin-resistant Streptococcus pneumoniae, and B. anthracis (anthrax); proof of concept established in animal studies.

Per-asset detail extracted from the 10-Q filed 2026-08-13. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Ibezapolstat
Lead indication	Clostridium Difficile Infection Recurrence
Lead phase	Phase 2
Active trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07513285	Phase 2	Recruiting	Sponsor	ACXP	—	Clostridium Difficile Infection Recurrence	—

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for Acurx Pharmaceuticals Inc. on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

ACXP — Acurx Pharmaceuticals Inc.